This is probably because SHP2 induces downregulation of other signaling factors, such as signal transducer and activator of transcription 3 (STAT3), which is also essential for glioma maintenance, and overactivation of SHP2 rather leads to repression of tumor growth, even when the MAPK pathway is activated. Here, STAT3 is linked to neoplasm.